Segundo o comunicado da Eli Lilly de 11 de dezembro de 2025, participantes com obesidade e artrose tratados com retatrutida 12mg perderam, em mdia, 28,7% do peso corporal (32,3kg ou 71,2lb) aps 68 semanas
The FDA Adverse Event Reporting System (FAERS) collects post-marketing safety reports, but such spontaneous reporting systems have inherent limitations and cannot establish causation or absence of risk
Key findings: Compared to matched controls: 12.8 higher odds of transfusion preterm birth (aOR ~1.8) No significant increase in reported PPH (recent cohort) Important nuance The lack of PPH signal doesnt mean no bleeding risk: Transfusion rates remain high Suggests bleeding + anemia (e.g., iron deficiency) may be underappreciated drivers What this tells us, even in modern care: VWD still impacts maternal outcomes Traditional endpoints (like PPH) may miss part of the picture Pre-delivery optimization (iron, hemostasis) matters as much as delivery management Clinical direction - Multidisciplinary care (Heme + MFM) - Routine iron deficiency screening - Better peripartum planning Ming Y Lim | G Bryce Christensen | George M
BPC-157 500MCG Capsules BPC-157 500MCG A pharmaceutical-grade peptide in a convenient 60-capsule container for advanced scientific research